PhaseRx, Inc. Presents at 15th Annual TIDES meeting in Boston
RNA Therapeutics as Personalized Medicine for the Treatment of Hepatocellular Carcinoma
Beta-catenin and c-MET have been associated with the development of hepatocellular carcinoma. Using PhaseRx’s SMARTT Polymer Technology®, siRNAs can be effectively delivered to HCC cells. Polymers formulated with b -catenin and c-MET siRNAs were evaluated in a HCC mouse model. Dose-dependent mRNA and protein KD following a single dose were observed in tumors in vivo. Repeat dose studies have shown potent anti-tumor efficacy as well as increased survival with good tolerability.